A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Inclusion criteria:

• Be more than or equal to (>=) 18 years of age (or the legal age of majority in thejurisdiction in which the study is taking place, whichever is greater)

• Have histologically or cytologically confirmed recurrent/metastatic (R/M) HNSCC thatis considered incurable by local therapies: a. eligible primary tumor locations arethe oral cavity, oropharynx, hypopharynx, or larynx; b. Must not have a primarytumor site of nasopharynx or primary tumor of unknown location; c. Must havedocumented local testing results per local regulations; d. Human papillomavirus (HPV) status must be known for participants with primary tumor location inoropharynx via p16 test, HPV DNA test, or high-risk HPV in situ hybridization (ISH).Any known p16, HPV DNA, or high-risk HPV ISH status of tumor must be negative

• Be treatment-naive for systemic therapy in the R/M setting

• Have an ECOG performance status of 0 or 1

• Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1

Exclusion criteria:

• Have an uncontrolled illness

• Have untreated brain metastases or history of known presence of leptomeningealdisease

• Have a history of clinically significant cardiovascular disease

• Inadequate organ or bone marrow function

• Known allergies, hypersensitivity, contraindications, or intolerance to excipientsof: Amivantamab, Pembrolizumab, Carboplatin, Cisplatin, 5-FU and Hyaluronidase